60 Degrees Pharma hits minimum enrollment trigger for interim readout in severe babesiosis tafenoquine trial

• 60 Degrees Pharmaceuticals reached the minimum 24-patient enrollment for an interim analysis in its hospitalized severe babesiosis trial of tafenoquine.
• Results have not been presented; an interim data readout is scheduled no later than Oct. 6, 2026.
• The interim review will assess whether tafenoquine speeds sustained clinical recovery, with a secondary look at parasite clearance, without detailing performance metrics.
• A positive primary endpoint could stop the study early; other outcomes could prompt added enrollment or a close for lack of expected benefit.
• The company plans an FDA meeting after the readout to discuss a potential supplemental NDA pathway for babesiosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.